Longeveron (NASDAQ:LGVN – Get Rating) and VG Life Sciences (OTCMKTS:VGLS – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, valuation, profitability and analyst recommendations.

Profitability

This table compares Longeveron and VG Life Sciences' net margins, return on equity and return on assets.

Insider and Institutional Ownership

2.1% of Longeveron shares are held by institutional investors. 41.6% of Longeveron shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

Longeveron presently has a consensus price target of $13.25, indicating a potential upside of 231.95%.

Earnings & Valuation

This table compares Longeveron and VG Life Sciences' revenue, earnings per share and valuation.

VG Life Sciences has lower revenue, but higher earnings than Longeveron.

Risk and Volatility

Longeveron has a beta of 0.65, meaning that its share price is 35% less volatile than the S&P 500. Comparatively, VG Life Sciences has a beta of 1.67, meaning that its share price is 67% more volatile than the S&P 500.

About Longeveron

(Get Rating)

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.

About VG Life Sciences

(Get Rating)

VG Life Sciences, Inc. engages as a drug discovery and development company. It focuses on Targeted Peptide Technology (TPT), and Metabolic Disruption Technology (MDT). The TPT deals with HIV/AIDS. The MDT helps to fight cancers with solid tumors in situations where the cancer is resistant to the initial cancer drug therapy. The company was founded by Haig Keledjian in 1994 and is headquartered in New York, NY.

Receive News & Ratings for Longeveron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Longeveron and related companies with MarketBeat.com's FREE daily email newsletter.